Truvada Growth Driven By Placement On First-Line Regimens, Gilead Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Truvada (emtricitabine/tenofovir disoproxil) brand awareness is close to 100% among HIV treatment community partly due to direct-to-consumer ads, which will continue throughout 2005, Gilead says. Most growth comes from treatment-naive patients, followed by Viread and Emtriva switches, firm says.